{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:21:06Z","timestamp":1790673666296,"version":"4.1.0"},"reference-count":38,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:00:00Z","timestamp":1612396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Small molecule kinase inhibitors (SMKIs) are widely used in oncology. Therapeutic drug monitoring (TDM) for SMKIs could reduce underexposure or overexposure. However, logistical issues such as timing of blood withdrawals hamper its implementation into clinical practice. Extrapolating a random concentration to a trough concentration using the elimination half-life could be a simple and easy way to overcome this problem. In our study plasma concentrations observed during 24 h blood sampling were used for extrapolation to trough levels. The objective was to demonstrate that extrapolation of randomly taken blood samples will lead to equivalent estimated trough samples compared to measured Cmin values. In total 2241 blood samples were analyzed. The estimated Ctrough levels of afatinib and sunitinib fulfilled the equivalence criteria if the samples were drawn after Tmax. The calculated Ctrough levels of erlotinib, imatinib and sorafenib met the equivalence criteria if they were taken, respectively, 12 h, 3 h and 10 h after drug intake. For regorafenib extrapolation was not feasible. In conclusion, extrapolation of randomly taken drug concentrations to a trough concentration using the mean elimination half-life is feasible for multiple SMKIs. Therefore, this simple method could positively contribute to the implementation of TDM in oncology.<\/jats:p>","DOI":"10.3390\/ph14020119","type":"journal-article","created":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T12:02:10Z","timestamp":1612440130000},"page":"119","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Feasibility of Extrapolating Randomly Taken Plasma Samples to Trough Levels for Therapeutic Drug Monitoring Purposes of Small Molecule Kinase Inhibitors"],"prefix":"10.3390","volume":"14","author":[{"given":"Ruben A. G.","family":"van Eerden","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, 3015GD Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2506-3852","authenticated-orcid":false,"given":"Esther","family":"Oomen-de Hoop","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, 3015GD Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aad","family":"Noordam","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, 3015GD Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5667-5697","authenticated-orcid":false,"given":"Ron H. J.","family":"Mathijssen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, 3015GD Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijn L. W.","family":"Koolen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, 3015GD Rotterdam, The Netherlands"},{"name":"Department of Hospital Pharmacy, Erasmus MC, University Medical Center, 3015GD Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40262-018-0683-0","article-title":"Therapeutic Drug Monitoring of Oral Anti-Hormonal Drugs in Oncology","volume":"58","author":"Groenland","year":"2019","journal-title":"Clin. Pharm."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/cpt.787","article-title":"Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology","volume":"102","author":"Verheijen","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Mueller-Schoell, A., Groenland, S.L., Scherf-Clavel, O., van Dyk, M., Huisinga, W., Michelet, R., Jaehde, U., Steeghs, N., Huitema, A.D.R., and Kloft, C. (2020). Therapeutic drug monitoring of oral targeted antineoplastic drugs. Eur. J. Clin. Pharmacol.","DOI":"10.1007\/s00228-020-03014-8"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5738","DOI":"10.1158\/1078-0432.CCR-16-1255","article-title":"Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients","volume":"22","author":"Verheijen","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s00228-019-02704-2","article-title":"Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine","volume":"75","author":"Groenland","year":"2019","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1038\/bjc.2014.194","article-title":"Pharmacokinetically guided sunitinib dosing: A feasibility study in patients with advanced solid tumours","volume":"110","author":"Lankheet","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/FTD.0000000000000004","article-title":"Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care","volume":"36","author":"Lankheet","year":"2014","journal-title":"Ther. Drug Monit."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s40262-017-0510-z","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing","volume":"56","author":"Verheijen","year":"2017","journal-title":"Clin. Pharm."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.drudis.2014.09.007","article-title":"Individualized dosing of tyrosine kinase inhibitors: Are we there yet?","volume":"20","author":"Guchelaar","year":"2015","journal-title":"Drug Discov. Today"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Hussaarts, K., Veerman, G.D.M., Jansman, F.G.A., van Gelder, T., Mathijssen, R.H.J., and van Leeuwen, R.W.F. (2019). Clinically relevant drug interactions with multikinase inhibitors: A review. Ther. Adv. Med. Oncol., 11.","DOI":"10.1177\/1758835918818347"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/FTD.0000000000000654","article-title":"Therapeutic Drug Monitoring of Oral Anticancer Drugs: The Dutch Pharmacology Oncology Group-Therapeutic Drug Monitoring Protocol for a Prospective Study","volume":"41","author":"Groenland","year":"2019","journal-title":"Ther. Drug Monit."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2125.2011.04080.x","article-title":"Therapeutic drug monitoring of antimicrobials","volume":"73","author":"Roberts","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","article-title":"Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report","volume":"41","author":"Brunet","year":"2019","journal-title":"Ther. Drug Monit."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ejca.2020.05.025","article-title":"Therapeutic drug monitoring of imatinib in patients with gastrointestinal stromal tumours\u2014Results from daily clinical practice","volume":"136","author":"IJzerman","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2165\/00003088-200544020-00002","article-title":"Individualised cancer chemotherapy: Strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: A review","volume":"44","author":"Huitema","year":"2005","journal-title":"Clin. Pharm."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/FTD.0b013e3181b2c8cf","article-title":"A therapeutic drug monitoring algorithm for refining the imatinib trough level obtained at different sampling times","volume":"31","author":"Wang","year":"2009","journal-title":"Ther. Drug Monit."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1002\/cpt.1331","article-title":"Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic Study","volume":"105","author":"Hussaarts","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/clpt.2011.42","article-title":"Environmental and genetic factors affecting transport of imatinib by OATP1A2","volume":"89","author":"Eechoute","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5780","DOI":"10.1158\/1078-0432.CCR-12-0490","article-title":"A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients","volume":"18","author":"Eechoute","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Hussaarts, K., van Doorn, L., Eechoute, K., Damman, J., Fu, Q., van Doorn, N., Eisenmann, E.D., Gibson, A.A., Oomen-de Hoop, E., and de Bruijn, P. (2020). Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12090788"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s40262-015-0239-5","article-title":"Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence","volume":"54","author":"Kloth","year":"2015","journal-title":"Clin. Pharm."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s40262-013-0111-4","article-title":"Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: The ClearSun study","volume":"53","author":"Kloth","year":"2014","journal-title":"Clin. Pharm."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1200\/JCO.2015.65.2560","article-title":"Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients with Non-Small-Cell Lung Cancer","volume":"34","author":"Peric","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Veerman, G.D.M., Hussaarts, K., Peric, R., Oomen-de Hoop, E., Landa, K.D., van der Leest, C.H., Broerse, S.D., Rutten, H.B., Belderbos, H.N.A., and Steendam, C.M.J. (2020). Influence of Cow\u2019s Milk and Esomeprazole on the Absorption of Erlotinib: A Randomized, Crossover Pharmacokinetic Study in Lung Cancer Patients. Clin. Pharm.","DOI":"10.1007\/s40262-020-00910-1"},{"key":"ref_25","unstructured":"(2020, December 16). BIO-GIO Study\u2014Netherlands Trial Register NL6336 (NTR6652). Available online: https:\/\/www.trialregister.nl\/trial\/6336."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00280-014-2403-2","article-title":"Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors","volume":"73","author":"Freiwald","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"6073","DOI":"10.1158\/1078-0432.CCR-05-2596","article-title":"Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors","volume":"12","author":"Delbaldo","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1158\/1078-0432.CCR-08-1893","article-title":"A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients","volume":"15","author":"Houk","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.clinthera.2020.05.008","article-title":"Population Pharmacokinetics of Erlotinib in Patients with Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients","volume":"42","author":"Evelina","year":"2020","journal-title":"Clin. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/clpt.2014.47","article-title":"Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662","volume":"96","author":"Diekstra","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"S1558","DOI":"10.21037\/tcr.2017.09.09","article-title":"The role of ethnicity in personalized dosing of small molecule tyrosine kinase inhibitors used in oncology","volume":"6","author":"Touma","year":"2017","journal-title":"Transl. Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1365-2125.2011.03963.x","article-title":"Population pharmacokinetic analysis of sorafenib in patients with solid tumours","volume":"72","author":"Jain","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1111\/bcp.14334","article-title":"Population pharmacokinetics of regorafenib in solid tumours: Exposure in clinical practice considering enterohepatic circulation and food intake","volume":"86","author":"Keunecke","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/cts.12458","article-title":"Influence of OATP1B1 Function on the Disposition of Sorafenib-beta-D-Glucuronide","volume":"10","author":"Bins","year":"2017","journal-title":"Clin. Transl. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1046\/j.1472-8206.2002.00086.x","article-title":"Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs","volume":"16","author":"Rousseau","year":"2002","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/imj.13412","article-title":"Individualised medicine: Why we need Bayesian dosing","volume":"47","author":"Donagher","year":"2017","journal-title":"Intern. Med. J."},{"key":"ref_37","unstructured":"Agency, E.M. (2021, January 25). Guideline on the Investigation of Bioequivalence. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-bioequivalence-rev1_en.pdf."},{"key":"ref_38","unstructured":"Agency, E.M. (2021, January 25). Validation of Analytical Procedures. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-q-2-r1-validation-analytical-procedures-text-methodology-step-5_en.pdf."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/14\/2\/119\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:19:57Z","timestamp":1760159997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/14\/2\/119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,4]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["ph14020119"],"URL":"https:\/\/doi.org\/10.3390\/ph14020119","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,4]]}}}